{"pub": "thehill", "url": "https://thehill.com/policy/healthcare/466466-drugmaker-recalls-heartburn-drug-zantac-over-cancer-concerns", "downloaded_at": "2019-10-19 11:08:07.698633+00:00", "title": "Drugmaker recalls heartburn drug Zantac over cancer concerns", "language": "en", "text": "The drugmaker Sanofi announced Friday that it is recalling the heartburn drug Zantac in the United States and Canada because of concerns it could contain low levels of a cancer-causing chemical.\n\nThe company said in a statement that the recall was being conducted as a \u201cprecautionary measure.\u201d\n\nADVERTISEMENT\n\nIn September, the Food and Drug Administration (FDA) issued an alert that Zantac, which contains ranitidine, could contain low levels of the carcinogen nitrosodimethylamine.\n\nSome retailers, like CVS, then stopped selling the drug. Sanofi said it has decided to recall the drug \u201cdue to inconsistencies in preliminary test results.\u201d\n\nThe company said that \u201cevaluations are ongoing.\u201d\n\nThe FDA said earlier this month that it is \u201ccontinuing to test\u201d the drug and had asked manufacturers to conduct testing as well.\n\n\u201cSanofi is committed to transparency and will continue to communicate results with health authorities from the ongoing testing, and work with them to make informed decisions based on available data and evidence,\u201d the company said.\n\n\u201cSanofi encourages anyone using Zantac OTC to speak with their health care providers or pharmacists if they have any additional questions,\u201d the company said.\n\n", "description": "The drugmaker Sanofi announced Friday that it is recalling the heartburn drug Zantac in the United States and Canada because of concerns it could contain low levels of a cancer-causing chemical.", "authors": [], "top_image": "https://thehill.com/sites/default/files/zantac_101819getty_0.jpg", "published_at": "2019-10-18"}